Daily Squeeze Report
The top short-squeeze candidates among US-listed equities, published daily from authoritative FINRA short-interest data.
- September 9, 2026
Squeeze Report — September 9, 2026
The tape is crowded with high-short-interest biotechs and broken balance sheets, but the real signal is divergence: NVAX and SRPT are already squeezing while shorts quietly cover, leaving GRPN and XXI as the most fragile float squeezes. The catalyst calendar is thin until late September, so positioning—not news—is driving these names.
Read the report → - September 8, 2026
Squeeze Report — September 8, 2026
The tape is crowded with high-short-interest names, but conviction is scarce: cheap borrow and dilution overhangs are capping most setups. CHPT and ORIC stand out for having both hard squeeze data and near-term catalysts, while the energy complex (UUUU, AESI, CRK) is the only sector cluster showing rotation tailwinds.
Read the report → - September 7, 2026
Squeeze Report — September 7, 2026
Biotech dominates today's squeeze screen, but the setups are mostly pre-paid: crowded options, cheap borrow, and heavy dilution overhangs cap upside across SLS, SRPT, TGTX, and AMLX. The more interesting tension sits in GRRR, where a 40% short interest and rising borrow costs collide with unresolved fraud allegations.
Read the report → - September 4, 2026
Squeeze Report — September 4, 2026
The tape is bifurcated: energy and AI-adjacent names with hard catalysts (CRK, AI) are drawing real squeeze interest, while a crowded biotech cohort (SLDB, ORIC, GLUE, PHAT) screens hot on short interest but is fighting dilution overhangs and a sector rotation that keeps conviction capped.
Read the report → - September 3, 2026
Squeeze Report — September 3, 2026
Biotech dominates today's high-conviction squeeze watch, but the setups are bifurcated: TGTX and VIR show shorts pressing into strength near 52-week highs, while TNGX and UNCY carry extreme short interest undermined by cheap borrow and heavy ATM overhang. The real story is how many of these 'squeeze' candidates are already seeing shorts cover.
Read the report → - September 2, 2026
Squeeze Report — September 2, 2026
Biotech dominates today's high-conviction squeeze candidates, with FDA decisions and Phase 3 readouts clustering as the catalysts most likely to force covering. Outside the sector, GRRR's 26.85% borrow fee and CRK's $1.65B asset sale stand out as the only non-biotech setups with real teeth.
Read the report → - September 1, 2026
Squeeze Report — September 1, 2026
The tape is crowded with high-short-interest names that look better on a screener than in the borrow book. The real story is the gap between headline short interest and actual covering pressure — shorts are already exiting several of these setups, and cheap borrow plus dilution overhangs are capping the upside.
Read the report → - August 31, 2026
Squeeze Report — August 31, 2026
SLDB tops the short-squeeze leaderboard for August 31, 2026 with 22% of its float sold short. 1 name scored in the hot zone (≥80) across 15 ranked tickers.
Read the report → - August 28, 2026
Squeeze Report — August 28, 2026
The tape is bifurcated: a cluster of pre-revenue biotechs (SLS, ORIC, SLDB) are running hot into binary catalysts while heavily diluted balance sheets cap forced-covering risk. Elsewhere, high static short interest in WHR, PLAY, and GO is undercut by cheap borrow and already-declining short bases.
Read the report → - August 27, 2026
Squeeze Report — August 27, 2026
The tape is littered with high short interest but hollow setups. ABSI and VERA are the only names where the squeeze math is matched by a live catalyst, while post-earnings fades in KSS and CRSR show shorts are not panicking.
Read the report → - August 26, 2026
Squeeze Report — August 26, 2026
Biotech dominates the high-conviction end of today's book, with TGTX, CELC, SRPT, and SVRA all pairing elevated short interest with near-term FDA or data catalysts. The clearest tension is between crowded shorts and cheap borrow — several names look squeezable on positioning but lack the options-market confirmation that typically precedes a forced unwind.
Read the report → - August 25, 2026
Squeeze Report — August 25, 2026
The tape is crowded with high-short-interest biotechs, but the fuel is mostly stale or diluted. TTAN stands out as the only name where borrow pressure, a hard catalyst, and institutional accumulation align — though insider selling caps the ceiling.
Read the report → - August 24, 2026
Squeeze Report — August 24, 2026
The tape is bifurcated: event-driven squeezes in GRRR and WEN are live today, while a cluster of biotech names (SLS, SVRA, SLDB) lean on binary catalysts that could cut either way. The strongest fuel sits where short interest is high but borrow is still cheap, leaving forced covering dependent on news, not mechanics.
Read the report → - August 21, 2026
Squeeze Report — August 21, 2026
The tape is bifurcated: a handful of high-short-interest names are already up 20–45% in 20 days, meaning the squeeze has largely paid out before the crowd arrives. The real edge today is in the setups where positioning is hot but the borrow is still cheap and the catalyst is dated — GRRR, RLAY, and ASST are the only names where the squeeze math still has room to run.
Read the report → - August 20, 2026
Squeeze Report — August 20, 2026
GRRR and FOUR are the only names pairing elevated borrow stress with a hard, near-dated catalyst — earnings today and this quarter, respectively. The rest of the tape is a study in why high short interest alone isn't a trade: BSY, TDAY, ABR, and TDC all lack the funding pressure or sector sponsorship to force a squeeze.
Read the report → - August 19, 2026
Squeeze Report — August 19, 2026
The tape is bifurcated: a handful of biotech names (IMRX, SLDB, RLAY) carry extreme days-to-cover but face dilution overhangs that cap squeezes, while crowded consumer and tech shorts (GO, DUOL, KSS) show live catalysts but cheap borrow. The most actionable setups are catalyst-driven, not borrow-driven.
Read the report → - August 18, 2026
Squeeze Report — August 18, 2026
The tape is crowded with high-short-interest names, but the real story is the absence of forced covering: borrow is cheap almost everywhere, and the strongest setups are being undercut by insider selling and dilution. The exceptions are PDYN and GRRR, where actual borrow stress is showing up.
Read the report → - August 17, 2026
Squeeze Report — August 17, 2026
The tape is crowded with high-short-interest biotechs, but the real story is how many of these setups are already decaying: stale FINRA prints, cheap borrow, and dilution overhangs are blunting forced-covering pressure. The strongest mechanical squeezes — GO, IMRX, IMVT — all lack a near-term spark, while the only imminent binary, EYPT's DURAVYU readout, is priced like a non-event.
Read the report → - August 14, 2026
Squeeze Report — August 14, 2026
The tape is crowded with high-short-interest names that have already run, leaving fragile setups where borrow is cheap and shorts are covering. The most interesting tension sits in BIRK and REPL, where fresh catalysts collided with immediate dilution events.
Read the report → - August 13, 2026
Squeeze Report — August 13, 2026
Biotech dominates the squeeze scanner today, with a cluster of pre-catalyst setups—SVRA’s November PDUFA, EYPT’s imminent LUGANO data, and ABCL’s post-data dilution—highlighting the asymmetric risk/reward in the sector. Outside healthcare, UPWK’s convertible maturity and shrinking float offer a rare non-biotech setup, while extreme SI names like IBRX and TNGX remain fundamentally broken value trap
Read the report → - August 12, 2026
Squeeze Report — August 12, 2026
Today’s slate is dominated by biotech and pre-revenue names where the borrow is cheap and the bear case is formidable, creating a landscape of potential slow-burn squeezes rather than imminent gamma explosions. The standout setups hinge on binary clinical catalysts—IMVT’s CLE data and SRPT’s sNDA decision—where a positive readout could ignite a violent repositioning against complacent shorts.
Read the report → - August 11, 2026
Squeeze Report — August 11, 2026
Biotech dominates the high-conviction squeeze list, but the real story is the tension between extreme short positioning and aggressive dilution—NEO's convertible cap, NTLA's ATM overhang, and IBRX's going-concern warning all pit powder-keg technicals against heavy fundamental supply.
Read the report → - August 10, 2026
Squeeze Report — August 10, 2026
Biotech dominates today's book, but the real story is the divergence between textbook setups and actual price action. TWST and TMDX show shorts getting squeezed in real-time, while REPL proves that even an FDA approval can't ignite a squeeze if the catalyst is fully priced.
Read the report → - August 7, 2026
Squeeze Report — August 7, 2026
Biotech and healthcare names dominate today's high-conviction docket, clustering around binary FDA and earnings catalysts. The standout setup is LQDA, where shorts are pressing into a 130% YTD rally ahead of an Aug 12 earnings report, while REPL's post-approval hangover shows how quickly a squeeze thesis can deflate.
Read the report → - August 6, 2026
Squeeze Report — August 6, 2026
Today's slate is a study in asymmetry: TNDM's after-close print offers the most immediate, high-volatility setup, while the broader list is littered with broken biotechs where cheap borrow and insider selling neuter textbook short-interest optics.
Read the report → - August 5, 2026
Squeeze Report — August 5, 2026
Earnings season is compressing multiple high-short-interest names into a tight window, with GRPN, CRSR, DBX, FA, and BKSY all reporting by August 6. The standout setup is GRPN, where a 66.7% short interest collides with a deeply shrunken float and a low-bar earnings catalyst, though fundamental fragility keeps it a high-wire act.
Read the report → - August 4, 2026
Squeeze Report — August 4, 2026
Today's slate is dominated by biotech and healthcare names with elevated short interest, but the conviction is uniformly low—cheap borrow and convertible arb overhangs are the rule, not the exception. The standout is VRDN, where a fresh FDA approval and a complacent short base collide ahead of tomorrow's earnings.
Read the report → - August 3, 2026
Squeeze Report — August 3, 2026
Earnings season is delivering a dense cluster of binary events, with IT, VYX, PGEN, TMDX, and TVTX all reporting by August 6. The standout setup is the collision of extreme days-to-cover and active buybacks in names like FOUR and NTST, though fundamental fragility keeps most in the medium-confidence tier.
Read the report → - July 31, 2026
Squeeze Report — July 31, 2026
A bifurcated day for squeeze candidates: biotech pre-earnings plays (CRVS, IMVT, SNDX) show coiled springs with tight borrow and near-term catalysts, while heavily-shorted tech names (TEM, CRSR) are undermined by cheap borrow, declining short interest, and fundamental decay. The market’s rotation into healthcare is providing a tailwind for the right setups, but the wrong ones—like AESI and FMC—are
Read the report → - July 30, 2026
Squeeze Report — July 30, 2026
Today's slate is a study in asymmetry: a cluster of high-short-interest names face imminent earnings, but the real story is the cost of carry. Borrow fees are near zero across the board, meaning shorts feel no heat despite elevated days-to-cover — the catalysts must do all the work.
Read the report → - July 29, 2026
Squeeze Report — July 29, 2026
A cluster of healthcare shorts face their reckoning next week as TNDM, NTLA, NVAX, and CRVS all report earnings against elevated short interest and days-to-cover. The standout setup is TNDM, where a 20-day rally and cheap options overlay a 53% squeeze base rate ahead of its August 6 print.
Read the report → - July 28, 2026
Squeeze Report — July 28, 2026
Today's book is dominated by pre-earnings tension, with 18 of 24 names reporting within two weeks. The standout setups are GRPN's extreme 66.7% short interest ahead of its AI-restructuring update and NTST's 22-day cover facing mechanical index buying, while the biotech cluster shows elevated risk from dilution and fading sector momentum.
Read the report → - July 27, 2026
Squeeze Report — July 27, 2026
Biotech and healthcare names dominate today’s squeeze scan, but the setups are riddled with dilution overhangs, declining short interest, and a punishing sector rotation. The most compelling mechanics belong to ORIC and KURA, yet even their high short interest and days-to-cover are tempered by bearish fundamentals and macro headwinds, making pure squeeze plays scarce.
Read the report → - July 24, 2026
Squeeze Report — July 24, 2026
Biotech dominates today's book, but the real tension is between extreme positioning and fragile fundamentals. The highest-conviction names—CADL, GRPN, IBRX—pair triple-digit short interest or massive rallies with dilution overhangs and going-concern warnings, making the next earnings catalyst a binary event.
Read the report → - July 23, 2026
Squeeze Report — July 23, 2026
Today's squeeze landscape is a study in extremes: a single high-conviction biotech (SRRK) faces a binary FDA facility decision that could ignite a 19% short interest, while the rest of the field is littered with low-confidence setups undermined by cheap borrow, declining short positions, or overwhelming dilution. The clustering of Q2 earnings catalysts across ACDC, IOVA, and STEP offers potential
Read the report → - July 9, 2026
Squeeze Report — July 9, 2026
This week’s high-confidence squeeze candidate, BCRX, stands alone with a genuine powder keg setup ahead of its Q2 earnings, while the rest of the list is littered with fundamentally broken names where high short interest is more a symptom than a setup. The regime remains biotech-heavy, but only BCRX combines a viable catalyst with the kind of days-to-cover that could force a reckoning.
Read the report → - July 8, 2026
Squeeze Report — July 8, 2026
A wave of heavily shorted names—from biotech to consumer—are rallying into catalysts, but the real tension is between those where shorts are trapped (TGTX, WEN) and those where the squeeze may have already deflated (GRPN, ACHC). The most interesting setups combine rising short interest with a credible fundamental trigger, not just a high SI%.
Read the report → - July 7, 2026
Squeeze Report — July 7, 2026
Today’s scan is a tale of two markets: a handful of heavily shorted REITs and biotechs are coiled near potential fundamental catalysts, while a larger group of high-float-short names is undermined by cheap borrow, active dilution, or a market regime that’s left them behind. The standout is NTST, where a 26-day cover on a net-lease name collides with an imminent earnings print and a maturity wall.
Read the report → - July 6, 2026
Squeeze Report — July 6, 2026
Biotech dominates today's book with a cluster of binary PDUFA dates and Q2 earnings acting as potential flashpoints for heavily shorted, cash-burning names. The standout setups pit extreme borrow stress and imminent catalysts against massive dilution overhangs, making the next few weeks a high-stakes pressure test for trapped shorts.
Read the report → - July 3, 2026
Squeeze Report — July 3, 2026
A cluster of biotech and healthcare names (IBRX, SGMT, CRVS, NEO) dominates the top of the list, but the conviction is split: IBRX and SGMT offer genuine squeeze math with fundamental fragility, while NEO and ORKA show that a high squeeze score alone is a trap if short interest is already declining or negligible. The most actionable setups today pair extreme cost-to-borrow with a specific, near-te
Read the report → - July 2, 2026
Squeeze Report — July 2, 2026
Today's book is top-heavy with biotech and healthcare-services names carrying elevated short interest into imminent catalysts, but the conviction spread is wide. The standout is CELC's binary PDUFA on July 17, while IMVT and BEAM offer high DTC setups tempered by credible bear cases and dilution risk.
Read the report → - July 1, 2026
Squeeze Report — July 1, 2026
Biotech dominates today's book with a cluster of binary FDA catalysts and clinical readouts, but the conviction is highest where fundamental momentum backs the technical squeeze—VERA's PDUFA and NEO's earnings beat-and-raise setup stand out. Elsewhere, heavy dilution and insider selling keep many high-short-interest names in the 'prove it' column.
Read the report → - June 30, 2026
Squeeze Report — June 30, 2026
Biotech dominates today's high-conviction squeeze list, with BEAM and ORKA leading a cluster of clinical-stage names where surging short interest is colliding with imminent data readouts. Outside the sector, FRMM's 95% short-interest spike and LION's blockbuster-fueled rally stand out as the most combustible non-biotech setups.
Read the report → - June 29, 2026
Squeeze Report — June 29, 2026
Biotech small-caps dominate today's squeeze radar, with a cluster of high-conviction names like CADL, VERA, and NEO all facing imminent, binary catalysts that could violently punish entrenched shorts. The standout setup is CADL, where heavy insider buying collides with a pivotal BLA submission, while VERA's PDUFA date next week creates a high-stakes, time-compressed pressure cooker.
Read the report → - June 26, 2026
Squeeze Report — June 26, 2026
Biotech dominates today's book with a dense cluster of pre-revenue, high-burn names facing binary FDA or data catalysts, but the real tension sits in names like FRMM and GPGI where extreme short interest collides with cheap borrow and dilution overhangs.
Read the report → - June 25, 2026
Squeeze Report — June 25, 2026
Biotech dominates the conviction curve today, but the setups are uniformly haunted by dilution overhangs and stale short data. The most acute technical squeeze—ORIC with 45% short interest and 17 days to cover—is simultaneously the most fundamentally compromised by an active ATM, making the high-verdict call a pure wager on a program update surprising a complacent short base.
Read the report → - June 24, 2026
Squeeze Report — June 24, 2026
Today's board is a biotech-heavy squeeze watch, but the real tension sits between extreme technical setups and deep fundamental cracks. NTLA and CADL offer the highest-conviction pure plays on imminent clinical catalysts, while AVTX's 58% headline short interest is likely a phantom figure post-offering.
Read the report → - June 23, 2026
Squeeze Report — June 23, 2026
Biotech dominates the squeeze radar today, with RZLT and TGTX leading a pack of high-conviction clinical-stage names. The clustering of binary catalysts—from RZLT’s upLIFT data to BHVN’s regulatory update—suggests a sector-wide volatility event is brewing, while ARRY and SEI offer non-biotech counterpoints with their own earnings-driven dislocation.
Read the report → - June 22, 2026
Squeeze Report — June 22, 2026
Biotech dominates today's book with a cluster of high-short-interest names riding sector rotation, but the real tension sits in housing-linked MBC where a 28% short base collides with a 27% rally and a rare insider buying cluster. Elsewhere, GPGI's 15-day cover and 20% surge are textbook, yet the fundamental fragility underneath is extreme.
Read the report → - June 19, 2026
Squeeze Report — June 19, 2026
Today's list is dominated by earnings catalysts clustered in late July and early August, but the real tension sits in names where massive dilution overhangs collide with surging prices — CORZ, SEI, and COHU all show shorts trapped in rallies while staring down convertible note walls.
Read the report → - June 18, 2026
Squeeze Report — June 18, 2026
Biotech dominates the high-conviction squeeze setups today, with CADL and SRPT both sporting ~30% short interest and near-term catalysts that could ignite forced covering. Outside the sector, LYFT’s shrinking float from aggressive buybacks adds an interesting twist to an otherwise cooling tech-squeeze regime.
Read the report → - June 17, 2026
Squeeze Report — June 17, 2026
Today's squeeze board is dominated by earnings catalysts clustering in early August, but the most combustible setups are in names where price action has already inflicted pain on shorts — NEO, RHI, and FRMM all show 20-day surges exceeding 23% against double-digit days-to-cover. The real tension sits between cooling borrow costs and still-elevated short interest, making the next earnings prints bi
Read the report → - June 16, 2026
Squeeze Report — June 16, 2026
Today's slate is dominated by biotech and consumer-discretionary names with extreme short interest but weak borrow dynamics — textbook paper tigers. The standout is TGTX, where a squeeze already appears in motion ahead of Q2 earnings, while RH and ORIC show shorts doubling down into fundamental deterioration.
Read the report → - June 15, 2026
Squeeze Report — June 15, 2026
Today's book is front-loaded with textbook technical squeezes, but the real story is the cluster of buyback-driven float compression plays. In particular, FRMM's aggressive repurchase, TRIP's merger-driven share reduction, and METC's dormant buyback are all mechanisms that can spark a forced covering cascade even where fundamentals are thin.
Read the report → - June 12, 2026
Squeeze Report — June 12, 2026
Today's board is dominated by biotech and healthcare names with elevated short interest, but the real tension sits in a handful of lodging and consumer stocks where fundamental beats are colliding with heavy bearish positioning. PK, GO, and CBRL stand out as rare non-biotech squeeze candidates with actual earnings momentum, while NRIX and ORKA offer the highest-conviction biotech plays backed by f
Read the report → - June 12, 2026
Squeeze Report — June 11, 2026
Today's squeeze radar is split between names where the trade is already moving (REPL's 107% surge, AI's 23% pop) and those where a catalyst is still needed to ignite the powder keg. The standout tension is in NIQ and SOC: both have the raw short-interest fuel, but one is backed by insider conviction while the other faces active regulatory and dilution headwinds.
Read the report →